Exenatide (Byetta) As a Novel Treatment Option for Type 2 Diabetes Mellitus (Pharmacology Notes) (Clinical Report)

Exenatide (Byetta) As a Novel Treatment Option for Type 2 Diabetes Mellitus (Pharmacology Notes) (Clinical Report)

Exenatide is the first drug in the incretin mimetic class and is indicated for treatment of type 2 diabetes mellitus. Although structurally similar to the native glucagon-like peptide, this synthetic form has a much longer duration of action. Randomized trials have shown exenatide to be efficacious in improving glycemic control when combined with either metformin or a sulfonylurea. The dose is initially 5 mcg subcutaneously twice daily and may be titrated to 10 mcg subcutaneously twice daily to achieve better diabetes management. Nausea, vomiting, and diarrhea were the most common adverse events reported with exenatide therapy. Exenatide is not associated with hypoglycemia, which may provide advantages over adding insulin to a sulfonylurea or metformin. The American Diabetes Association estimates that 17 million people in the USA have type 2 diabetes (1). Currently, the first-line oral agents for type 2 diabetes are metformin and sulfonylureas. Other therapeutic options include thiazolidinediones and insulin. Despite best efforts, monotherapy or combination therapy of metformin and a sulfonylurea fails in many patients. This presents a problem because many second- and third-line agents may cause weight gain, hypoglycemia, and other adverse effects. Exenatide (Byetta) is the first in a new class of incretin peptide mimetics (glucagon-like polypeptide-1 [GLP-1] receptor agonists) available in the USA. It was approved by the Food and Drug Administration (FDA) in April 2005 for adjunctive glycemic control in patients with type 2 diabetes mellitus who are taking metformin, a sulfonylurea, or a combination of metformin and a sulfonylurea (2).

Exenatide (Byetta) As a Novel Treatment Option for Type 2 Diabetes Mellitus (Pharmacology Notes) (Clinical Report)



Here is Download Link

The Gila Monster


The Gila Monster Read Online Download

Author by : Jake Miller
Languange Used : en
Release Date : 2003
Publisher by : The Rosen Publishing Group






Incretin Based Therapies


Incretin Based Therapies Read Online Download

Author by : Sanjay Kalra
Languange Used : en
Release Date : 2013-03-31
Publisher by : JP Medical Ltd






Management Of Type 2 Diabetes Mellitus E Book


Management Of Type 2 Diabetes Mellitus E Book Read Online Download

Author by : Steven Levene
Languange Used : en
Release Date : 2011-11-29
Publisher by : Elsevier Health Sciences






Saunders Comprehensive Review For The Nclex Rn Examination E Book


Saunders Comprehensive Review For The Nclex Rn Examination E Book Read Online Download

Author by : Linda Anne Silvestri
Languange Used : en
Release Date : 2013-12-07
Publisher by : Elsevier Health Sciences






Medical Management Of Type 2 Diabetes


Medical Management Of Type 2 Diabetes Read Online Download

Author by : Charles Burant
Languange Used : en
Release Date : 2012-06-05
Publisher by : American Diabetes Association






Managing Clinical Problems In Diabetes


Managing Clinical Problems In Diabetes Read Online Download

Author by : Trisha Dunning
Languange Used : en
Release Date : 2008-04-30
Publisher by : John Wiley & Sons






Obesity And Diabetes Mellitus


Obesity And Diabetes Mellitus Read Online Download

Author by : E. I. Sokolov
Languange Used : en
Release Date : 1997-04
Publisher by : VSP






Leave a Reply

Your email address will not be published. Required fields are marked *